Valuation: Integrity Applications, Inc.

Market Cap 2M 1.75M 1.61M 1.5M 2.84M 191M 2.89M 19.32M 7.51M 93.74M 7.52M 7.36M 323M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -1.93M -1.69M -1.55M -1.45M -2.75M -184M -2.79M -18.65M -7.25M -90.52M -7.26M -7.1M -312M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.06%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 59 -
Director of Finance/CFO 66 27/01/2025
Chief Operating Officer - 31/01/2025
Director TitleAgeSince
Director/Board Member 59 26/08/2024
Director/Board Member 56 24/08/2023
Chairman 63 12/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 2M
+1.70%+7.41%+3.12%+8.46% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+5.46%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +3.06%+5.99%+71.64%+104.13% 26.92B
Weighted average by Cap. +1.74%+6.31%+89.18%+131.90%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.75M -18.15M -16.92M -32.1M -2.15B -32.58M -218M -84.73M -1.06B -84.82M -83M -3.64B -19.39M -16.95M -15.58M -14.52M -27.54M -1.85B -27.96M -187M -72.69M -907M -72.77M -71.21M -3.13B
Net Debt -5.35M -4.68M -4.3M -4.01M -7.6M -509M -7.71M -51.6M -20.06M -250M -20.08M -19.65M -863M -3.94M -3.44M -3.16M -2.95M -5.59M -375M -5.68M -37.97M -14.76M -184M -14.78M -14.46M -635M
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-